Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (BHC) delivers innovative healthcare solutions across gastroenterology, dermatology, and eye health through brands like Bausch + Lomb and Salix Pharmaceuticals. This page provides investors and industry professionals with a comprehensive repository of official company announcements and market-relevant updates.
Key resources include: earnings reports, regulatory filings, product launch announcements, and partnership developments. All content is sourced directly from BHC’s verified communications to ensure accuracy and timeliness.
Regularly updated with press releases spanning therapeutic advancements, financial results, and operational milestones. Bookmark this page to monitor BHC’s strategic initiatives within the global pharmaceutical landscape.
Bausch Health, Canada Inc. has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for public drug plan coverage of CABTREO, their triple-combination topical treatment for acne vulgaris. The agreement will enable coverage through all Canadian government drug plans, including provincial, territorial, and federal programs.
CABTREO is the first Health Canada-approved triple-combination topical acne treatment combining three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The prescription gel, administered once daily, is indicated for patients 12 years and older.
Bausch Health (NYSE/TSX: BHC) and its gastroenterology unit Salix Pharmaceuticals have launched 'IBS Symptoms Aren't Black and White: Living in the Gray,' a storytelling campaign for IBS Awareness Month in April 2025.
The initiative aims to highlight the complexities of Irritable Bowel Syndrome (IBS), a condition affecting up to 10% of the global population. The campaign will share patient stories on LinkedIn, focusing on how IBS impacts physical, emotional, social, and professional well-being.
Salix has partnered with the International Foundation for Gastrointestinal Disorders (IFFGD) to reduce stigma and encourage open discussions about IBS symptoms, including diarrhea, difficult bowel movements, abdominal pain, bloating, and urgency. The campaign seeks to empower patients to seek appropriate care and improve how IBS is perceived, diagnosed, and treated.
Bausch Health (NYSE/TSX: BHC) has scheduled the release of its first quarter 2025 financial results for Wednesday, April 30, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss the quarterly performance and provide a business update. All related materials will be accessible through the Investor Relations section of Bausch Health's website before the call begins.
Bausch Health (NYSE/TSX: BHC) has priced an upsized private offering of $4.4 billion in senior secured notes due 2032 with a 10.000% interest rate through its subsidiary 1261229 B.C. The offering was increased from the initial $4.0 billion target.
The company is also establishing new senior secured credit facilities, including a $500 million 5-year revolving credit facility and a $3.0 billion 5.5-year term loan facility (reduced from $3.4 billion). The proceeds will be used to repay existing credit agreements, redeem various senior secured notes, and for general corporate purposes.
The notes will be secured by a first-priority lien on the issuer's assets, including a 52.5% equity interest in Bausch + Lomb. The offering is expected to close on April 8, 2025, subject to customary conditions.
Bausch Health (NYSE/TSX: BHC) has announced conditional redemption notices for multiple series of senior notes, including 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 5.750% Senior Secured Notes due 2027, and 6.125% Senior Secured Notes due 2027. Additionally, its subsidiary 1375209 B.C. will redeem all outstanding 9.000% Senior Secured Notes due 2028.
The redemptions are contingent upon closing of new financing transactions, which include:
- $4,000 million in new senior secured notes due 2032
- $3,400 million from a new 5.5-year senior secured term loan B facility
The redemption process will be handled through the Depository Trust Company, with the company retaining the right to delay redemption dates if financing conditions are not met.
Bausch Health (BHC) has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion, consisting of a 5-year $400 million senior secured revolving credit facility and a $3.4 billion 5.5-year secured term loan B facility. The transaction, led by JPMorgan Chase Bank, is part of a broader refinancing initiative to address near- and mid-term maturities.
The facilities will be secured by first-priority liens on the borrower's assets, including Bausch + Lomb equity interest. The company plans to use proceeds to repay existing credit agreements, redeem various senior secured and senior notes due between 2025-2028, and for general corporate purposes. Bausch Health reduced net debt by nearly $1 billion in 2024 and reports seven consecutive quarters of top- and bottom-line growth.
Bausch Health (NYSE:BHC) has launched a $4.0 billion senior secured notes offering due 2032 through its subsidiary 1261229 B.C. The company is also seeking to establish new senior secured credit facilities, including a $400 million 5-year revolving credit facility and a $3,400 million 5.5-year term loan facility.
The notes will be secured by first-priority liens on the issuer's assets, including Bausch + Lomb equity interest, and guaranteed by various company subsidiaries. The proceeds, combined with the new term loan facility, will be used to:
- Repay and terminate existing credit agreement
- Redeem all existing senior secured and senior notes due 2025-2028
- Pay related fees and expenses
- Fund general corporate purposes
The notes will be offered exclusively to qualified institutional buyers in the US and non-US persons outside the United States, with specific exemptions for Canadian securities laws.
Bausch Health Companies Inc. (NYSE/TSX:BHC) has announced an update regarding its financing initiatives, revealing the engagement of J.P. Morgan to assist with its previously disclosed financing objectives. The company emphasizes that any potential transactions are subject to market conditions and other factors, with no guarantee of successful completion on acceptable terms.
Bausch Health (BHC) reported strong financial results for Q4 and full-year 2024, marking its seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA. Fourth quarter revenues reached $2.56 billion, up 6% on a reported basis and 9% organically, while full-year revenues hit $9.63 billion, increasing 10% on a reported basis and 8% organically.
The company achieved Q4 GAAP Net Income of $93 million, though recorded a full-year net loss of $46 million. Consolidated Adjusted EBITDA grew 8% to $935 million in Q4 and 10% to $3.31 billion for the full year. All business segments showed growth, with particularly strong performance from Solta Medical (34% growth) and Bausch + Lomb (9% growth) in Q4.
Bausch Health Companies (NYSE/TSX: BHC) has announced its participation in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida. The event is scheduled for Monday, February 24, 2025, at 8:45 a.m. EST.
The company will provide a live audio webcast of the event, which will be accessible through the Investor Relations section of Bausch Health's website. Interested parties can access the webcast at http://ir.bauschhealth.com/events-and-presentations. A replay of the event will be made available on the same investor relations website after the conference.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
